Stem cell transplantation outcomes 'improved with new drug regime'
12/11/2013

New research suggests that outcomes for patients who have undergone stem cell transplants from unrelated or mismatched donors could be improved with the use of a drug called bortezomib, also known as velcade. This is according to a study presented at the annual meeting of the American Society of Hematology.

Risk factor for liver cancer increased by diabetes across ethnic groups
12/11/2013

Diabetes was associated with an increased risk for developing a type of liver cancer called hepatocellular carcinoma, and this association was highest for Latinos, followed by Hawaiians, African-Americans, and Japanese-Americans, according to results presented at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.

New technique could help bring cancer biomarkers to clinic
12/11/2013

An international team of scientists led by Fred Hutchinson Cancer Research Center cancer proteomics expert Amanda Paulovich, M.D., has demonstrated the feasibility of large-scale, standardized protein measurements, which are necessary for validation of disease biomarkers and drug targets.

Gene discovered that plays a part in one per cent of all cancers
12/11/2013

Researchers have identified a gene that drives the development of tumours in over one per cent of all cancer patients. This is the first time that the gene CUX1 has been broadly linked to cancer development.The team discovered that, when CUX1 is deactivated, a biological pathway is activated that increases tumour growth.

Mechanism identified that is implicated in brain cancer and a drug that decreases brain tumor growth
12/11/2013

Researchers at the University of Calgary's Hotchkiss Brain Institute (HBI) have made a discovery that could lead to better treatment for patients suffering from brain cancer.Despite current treatment strategies, the median survival for patients with the most aggressive brain cancer - called glioblastoma, is 15 months. Less than five per cent of patients survive beyond five years.

Association between oncometabolite accumulation and breast cancer prognosis
12/11/2013

The metabolic profile of cancer cells can be used to develop therapies and identify biomarkers associated with cancer outcome. In this issue of the Journal of Clinical Investigation Stefan Ambs and colleagues at the National Cancer Institute discovered an association between the oncometabolite 2-hydroxyglutarate (2-HG) levels, DNA methylation patterns, and breast cancer prognosis.

Biomarker linked to aggressive breast cancers, poor outcomes in African-Americans
12/11/2013

Among African-American women with breast cancer, increased levels of the protein HSET were associated with worse breast cancer outcomes, according to results presented at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.

Guideline-recommended breast cancer treatment affected by economic factors
12/11/2013

Women with interruptions in health insurance coverage or with low income levels had a significantly increased likelihood of failing to receive breast cancer care that is in concordance with recommended treatment guidelines, according to results presented at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.

Advanced-stage ovarian cancer treated with targeted nanomedicine
12/10/2013

Researchers at Rutgers, the State University of New Jersey, have used a targeted nanomedicine approach to deliver small molecule drugs and successfully treat mice with deadly advanced-stage ovarian cancer.

Advanced-stage ovarian cancer treated with targeted nanomedicine
12/10/2013

Researchers at Rutgers, the State University of New Jersey, have used a targeted nanomedicine approach to deliver small molecule drugs and successfully treat mice with deadly advanced-stage ovarian cancer.